Cargando…
Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia
Hereditary hemorrhagic telangiectasia (HHT) is a rare angiogenic disorder causing chronic gastrointestinal bleeding, epistaxis, and severe anemia. Pazopanib is an oral multi-kinase angiogenesis inhibitor with promise to treat bleeding in HHT. We analyzed outcomes of HHT patients with the most severe...
Autores principales: | Parambil, Joseph G., Gossage, James R., McCrae, Keith R., Woodard, Troy D., Menon, K. V. Narayanan, Timmerman, Kasi L., Pederson, Douglas P., Sprecher, Dennis L., Al-Samkari, Hanny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295629/ https://www.ncbi.nlm.nih.gov/pubmed/34292451 http://dx.doi.org/10.1007/s10456-021-09807-4 |
Ejemplares similares
-
Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia
por: Faughnan, Marie E., et al.
Publicado: (2018) -
Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective
por: Kritharis, Athena, et al.
Publicado: (2018) -
An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study
por: Al-Samkari, Hanny, et al.
Publicado: (2020) -
A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders
por: Al‐Samkari, Hanny, et al.
Publicado: (2020) -
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias
por: Al-Samkari, Hanny, et al.
Publicado: (2021)